Protein markers of responsiveness to type III receptor tyrosine kinase inhibitors
US7833736B2 · kind B2 · utility
1Cited by
2References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 2, 2007 |
| Grant date | Nov 16, 2010 |
| Priority date | — |
| Expiry date | Jun 22, 2028 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The invention discloses ten (10) protein markers predictive of cancer resistance or responsiveness to Type III Receptor Tyrosine Kinase (RTK) inhibitors, and provides methods for identifying a cancer that is likely to be resistant to a Type III RTK-inhibiting therapeutic by examining expression and/or activity of one or more of the disclosed biomarkers in a biological sample from the cancer. Methods for identifying a compound that inhibits a cancer resistant to a Type III RTK-inhibiting therapeutic by determining the effect of the compound on one or more of the disclosed marker proteins are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.